Navigation Links
EnzySurge Receives FDA Approval for SilverStream(TM) Innovative Wound Management Solution
Date:12/15/2009

ROSH HA'AYIN, Israel, December 15 /PRNewswire/ -- EnzySurge Ltd. (EnzySurge), a provider of innovative solutions for the advanced chronic wound management market, announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its new SilverStream(TM) solution for prescription use. The FDA also cleared DermaSept, an Over-the-Counter version of the SilverStream product.

EnzySurge is the developer of the DermaStream(R) product line. DermaStream is a line of woundcare devices that allows for the continuous streaming of fresh therapeutic solutions, such as SilverStream, over the wound bed. The treatment provides constant removal of foreign material, exudate, micro-organisms and debris while creating negative pressure over the wound.

SilverStream may be either applied directly onto the wound or by the disposable DermaStream(R) device. According to Dr. Noa Hadar and Prof. Amihay Freeman who led the development, SilverStream is a hypertonic solution that contains very low concentration of preservative silver ions. "SilverStream has demonstrated remarkable capabilities by in-vitro testing inhibiting the growth of drug-resistant clinical bacterial strains, yeast and fungi upon contact in-vitro", stated Freeman.

SilverStream is intended for use under the supervision of a healthcare professional for management and moisturizing of wounds such as stage I-IV pressure ulcers, stasis ulcers, diabetic foot ulcers, post-surgical wounds, first and second degree burns, cuts abrasions and minor skin irritations. DermaSept is intended for the management and moisturizing of minor cuts, minor burns, abrasions and irritated areas.

"We are extremely pleased to receive FDA clearance for this unique product", says Amir Shiner Chief Executive Officer of EnzySurge. "We believe that SilverStream is a powerful wound management solution and will be a significant addition to the DermaStream(R) product line, which is intended to become the wound management system of choice. We are poised to launching SilverStream to market in 2010 with our U.S. partner, the Virginia Biosciences Commercialization Center."

The treatment of chronic wounds (such as diabetic, pressure and venous ulcers) is expensive, laborious and requires ongoing application and monitoring by a skilled caregiver. The global market for chronic wound products amounted $3.2 billion in 2008 and is expected grows to $4.1 billion by 2011.

"The recent achievements of EnzySurge and especially this FDA approval for SilverStream, represent significant opportunities for EnzySurge in the global wound care market in the near future", says Shiner.

About EnzySurge Ltd.

EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's DermaStream(R) platform offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced therapeutic solutions to a controlled wound environment. DermaStream is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment from debridement, through regeneration to wound closure. The EnzySurge product line is intended for use in hospitals, clinics and for home care.

    For further details:

    Amir Shiner, CEO
    Mobile: +972-54-3030294
    Tel: +972-3-6227600
    http://www.dermastream.com

SOURCE EnzySurge Ltd


'/>"/>
SOURCE EnzySurge Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Masimo Chairman and CEO Joe Kiani Receives 2009 Frost & Sullivan CEO of the Year Award
2. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
3. Greenway Medical Technologies PrimeSuite 2011 Receives CCHIT 2011 Comprehensive Certification
4. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
5. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
6. Dynatronics Receives 180-Day NASDAQ Extension
7. ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System
8. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens
9. Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress
10. SRI International Receives National Institutes of Health Grants to Develop Improved Tomographic Imaging Technology
11. Giant Eagle(R) Pharmacy Receives Award for Operational Excellence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... PUNE, India , February 8, 2016 ... to a new market research report "Ablation Technologies Market ... Application (Csardiovascular, Cancer, Pain Management, Cosmetic Surgery, Ophthalmology, Gynecology) ... report studies the global market over the forecast period ... reach $4.44 Billion by 2020, at CAGR of 10.5% ...
(Date:2/8/2016)... In a historic vote among its members this weekend, the ... cannabis cultivation facility and dispensary on tribal land near Southampton ... as a provider for patients in the state,s Medical Cannabis Program. ... provider for patients in the state,s Medical Cannabis Program. --> ... project and pursue designation from the State of New York ...
(Date:2/8/2016)... Feb. 8, 2016 http://www.researchandmarkets.com/research/x6mkjm/knee ... "Knee Reconstruction Devices Market by Product Type (Primary ... Geography (U.S., Canada, Eu-5, Japan, Bric, Turkey, Indonesia ... report to their offering. --> ... "Knee Reconstruction Devices Market by Product Type ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... , ... Steve Helwig & Associates Insurance & Financial, serving the families of ... up with Citizens Opposed to Domestic Abuse in support of its efforts to provide ... victimized by the fear of violence in their own homes, donations may now be ...
(Date:2/8/2016)... San Francisco, CA (PRWEB) , ... February 08, 2016 , ... ... helped raise $792,000 to help combat pancreatic cancer. , Gary D. Radine, who recently ... who also was the American Cancer Society’s 2015 CEO of the Year , ...
(Date:2/8/2016)... IL (PRWEB) , ... February 08, 2016 , ... ... conditions that co-occur frequently. While a significant number of women and men with ... not the trauma itself, that best predicts the development of an eating disorder. ...
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, PhD, ... healthcare companies can use newly released government data on populations and physicians to ... intervene and capture the value they create to succeed in new economic models ...
Breaking Medicine News(10 mins):